Dianthus Therapeutics is developing DNTH103, a monoclonal antibody that selectively inhibits the active form of the C1s protein in the classical complement pathway, allowing for targeted treatment of autoimmune diseases. This approach aims to reduce the frequency of administration to once every two weeks via subcutaneous injection, addressing the high treatment burden and safety concerns associated with current complement therapies.
Funding
$230M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current complement therapies for autoimmune diseases have limitations due to their broad inhibition of the complement system, leading to increased risk of infection and high treatment burden. Existing treatments often require high doses and frequent administration, which can be inconvenient for patients.
Solution
Dianthus Therapeutics is developing DNTH103, a clinical-stage monoclonal antibody engineered for selective inhibition of the classical complement pathway. DNTH103 targets only the active form of the C1s protein, a clinically validated complement target, while preserving the lectin and alternative pathways critical for defense against infections. This selective approach aims to reduce the risk of infection associated with broad complement inhibition. DNTH103 incorporates YTE half-life extension technology, designed to enable less frequent, self-administered subcutaneous injections, potentially improving patient convenience and adherence. The company is currently conducting Phase 2 trials in generalized Myasthenia Gravis (gMG), with plans to expand into Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Target Audience
The primary target audience includes patients with severe autoimmune diseases, particularly those with neuromuscular disorders such as generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy, as well as physicians specializing in these conditions.
Features
- Selective inhibition of the active form of C1s protein in the classical complement pathway
- Designed to preserve immune activity of the lectin and alternative complement pathways
- YTE half-life extension technology for less frequent dosing
- Potential for convenient subcutaneous, self-administered injection
- Clinical-stage development with ongoing Phase 2 trials in gMG and planned trials in MMN and CIDP
- Demonstrated improvement in neurotransmission and muscle contraction in preclinical models of gMG